JP6711488B2 - 慢性閉塞性気道疾患の治療のための６−ヒドロキシ−２，５，７，８−テトラメチルクロマン−化合物 - Google Patents

慢性閉塞性気道疾患の治療のための６−ヒドロキシ−２，５，７，８−テトラメチルクロマン−化合物 Download PDF

Info

Publication number
JP6711488B2
JP6711488B2 JP2016573765A JP2016573765A JP6711488B2 JP 6711488 B2 JP6711488 B2 JP 6711488B2 JP 2016573765 A JP2016573765 A JP 2016573765A JP 2016573765 A JP2016573765 A JP 2016573765A JP 6711488 B2 JP6711488 B2 JP 6711488B2
Authority
JP
Japan
Prior art keywords
sul
tetramethylchroman
hydroxy
compound
chronic obstructive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016573765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524674A (ja
JP2017524674A5 (https=
Inventor
デル フラーフ，アドリアヌス コルネリス ファン
デル フラーフ，アドリアヌス コルネリス ファン
シュミット，マルティナ
ヤン ウィレム ウーヴリンク，ヘリット
ヤン ウィレム ウーヴリンク，ヘリット
メールス，ヘルマヌス
ヘンク ヘニング，ロバート
ヘンク ヘニング，ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sulfateq BV
Original Assignee
Sulfateq BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulfateq BV filed Critical Sulfateq BV
Publication of JP2017524674A publication Critical patent/JP2017524674A/ja
Publication of JP2017524674A5 publication Critical patent/JP2017524674A5/ja
Application granted granted Critical
Publication of JP6711488B2 publication Critical patent/JP6711488B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2016573765A 2014-06-17 2015-06-17 慢性閉塞性気道疾患の治療のための６−ヒドロキシ−２，５，７，８−テトラメチルクロマン−化合物 Active JP6711488B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2013012A NL2013012B1 (en) 2014-06-17 2014-06-17 Compounds for the treatment of chronic obstructive airway diseases.
NL2013012 2014-06-17
PCT/EP2015/063579 WO2015193365A1 (en) 2014-06-17 2015-06-17 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases

Publications (3)

Publication Number Publication Date
JP2017524674A JP2017524674A (ja) 2017-08-31
JP2017524674A5 JP2017524674A5 (https=) 2018-07-26
JP6711488B2 true JP6711488B2 (ja) 2020-06-17

Family

ID=51358046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016573765A Active JP6711488B2 (ja) 2014-06-17 2015-06-17 慢性閉塞性気道疾患の治療のための６−ヒドロキシ−２，５，７，８−テトラメチルクロマン−化合物

Country Status (8)

Country Link
US (3) US9913841B2 (https=)
EP (1) EP3157518B1 (https=)
JP (1) JP6711488B2 (https=)
AU (1) AU2015276186B2 (https=)
CA (1) CA2952288C (https=)
ES (1) ES2784475T3 (https=)
NL (1) NL2013012B1 (https=)
WO (1) WO2015193365A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
EP3672592A1 (en) 2017-08-25 2020-07-01 Sulfateq B.V. 6-chromanol derivatives for use as a medicament
ES3013118T3 (en) 2017-08-25 2025-04-11 Sulfateq Bv Medicaments for the treatment of vasoconstriction related diseases or disorders
CA3079483A1 (en) * 2017-11-22 2019-05-31 Khondrion Ip B.V. Compounds as mpges-1 inhibitors
WO2021079300A1 (en) * 2019-10-23 2021-04-29 Chong Kun Dang Pharmaceutical Corp. Compositions for preventing or treating chronic obstructive pulmonary diseases (copd)
NL2031091B1 (en) * 2022-02-28 2023-09-07 Sulfateq Bv Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59222415A (ja) * 1983-05-31 1984-12-14 Kuraray Co Ltd 免疫調節剤
EP0202580B1 (en) * 1985-05-13 1990-03-28 Kuraray Co., Ltd. 3,4-dihydrobenzopyran derivatives
CA1338012C (en) * 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
FR2673629B1 (fr) * 1991-03-08 1993-05-07 Adir Nouveaux derives du benzopyrane leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2676056B1 (fr) * 1991-05-03 1993-07-16 Adir Nouveaux derives du benzopyranne leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US20040122059A1 (en) * 2002-10-01 2004-06-24 The Penn State Research Foundation PPAR-gamma ligands in the treatment of asthma and allergies
US20050065009A1 (en) 2002-11-05 2005-03-24 Lu Harry H. System and method for making a coiled strip of dunnage
WO2004045556A2 (en) * 2002-11-20 2004-06-03 Board Of Regents, The University Of Texas System Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens
WO2005033092A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
US7902330B2 (en) * 2004-02-13 2011-03-08 Albert Einstein College Of Medicine Of Yeshiva University Protein kinase inhibitors and methods for identifying same
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
EP3142646A1 (en) * 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol

Also Published As

Publication number Publication date
US10322124B2 (en) 2019-06-18
EP3157518A1 (en) 2017-04-26
WO2015193365A1 (en) 2015-12-23
CA2952288A1 (en) 2015-12-23
US9913841B2 (en) 2018-03-13
US20170151234A1 (en) 2017-06-01
NL2013012B1 (en) 2016-07-05
ES2784475T3 (es) 2020-09-28
JP2017524674A (ja) 2017-08-31
AU2015276186A1 (en) 2017-01-12
CA2952288C (en) 2024-01-23
US10426771B2 (en) 2019-10-01
AU2015276186B2 (en) 2020-09-10
US20180250294A1 (en) 2018-09-06
EP3157518B1 (en) 2020-01-15
US20180280384A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
JP6711488B2 (ja) 慢性閉塞性気道疾患の治療のための６−ヒドロキシ−２，５，７，８−テトラメチルクロマン−化合物
JP2014521724A (ja) 一過性受容器電位イオンチャネルｔｒｐａ１の阻害
JP2022507118A (ja) 呼吸器疾患の処置のための化合物及び組成物
JP6014589B2 (ja) スフィンゴシン１−リン酸（ｓ１ｐ）受容体上のリガンドとしての５−（ビフェニル−４−イル）−３−フェニル−１，２，４−オキサジアゾリル誘導体
JP2005526087A5 (https=)
JP2014511897A (ja) Ｃｎｓ障害の治療におけるジベンゾチアゼピン誘導体およびその使用
EP1634606A1 (en) Drug for airway administration
JP5931929B2 (ja) カテプシンｃ阻害剤
MXPA05004584A (es) Compuestos de amonio cuaternario.
JPH0688987B2 (ja) １、３―チアゾリジンのβ―カルボニルカルボキシアミド
JP2025515047A (ja) 線維症の治療方法
US9849098B2 (en) Compositions and methods for treating respiratory injury or disease
JP2021515811A (ja) ３”，５”−ジアルコシベンゾイル−３’−アミノ−３’−デオキシアデノシン−５’−三リン酸及びその医薬用途
JP6602297B2 (ja) ジフェニルオキシアルキルアミン誘導体およびアリールオキシアルキルアミン誘導体、薬学的組成物、慢性肺炎症性疾患を治療、予防、または阻止するための前記薬学的組成物の使用、ならびにそのような疾患を治療または予防するための方法
JPS5810577A (ja) ２−セノイルメルカプトプロピオニルグリシンのエステル、その製造法およびそれを有効成分とする医薬組成物
CN116162128A (zh) 一种抗病毒感染的核苷衍生物及其制备方法与用途
EP4565577A1 (en) Inhibitors and uses therefor
HK40101641A (zh) 一种抗流感病毒衍生物及其用途
HK40101641B (zh) 一种抗流感病毒衍生物及其用途
JP2021536467A (ja) 喘息またはパーキンソン病の処置のための方法および組成物
JPWO2004112791A1 (ja) 肺疾患の治療および／または予防剤
JP2020524135A (ja) 気管支拡張を誘発するためのｒａｃ１阻害剤及びその使用
WO2004087151A1 (ja) 医薬組成物
JPWO2004087147A1 (ja) 肺疾患の治療および／または予防剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180615

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180720

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200319

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200514

R150 Certificate of patent or registration of utility model

Ref document number: 6711488

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250